#USA #Los Angeles #Schall Law Firm #Securities Fraud #Soleno Therapeutics

Special Opportunity for Investors

In a notable development in the field of investment law, investors who suffered losses from their holdings in Soleno Therapeutics, Inc. now have a chance to take action. The Schall Law Firm, which specializes in representing shareholders, is spearheading a class action lawsuit against the company due to allegations of securities fraud. This case marks a critical opportunity for parties affected by the company's alleged misleading statements regarding its clinical trials and product safety.

Understanding the Background

Soleno Therapeutics, Inc., a publicly-traded biopharmaceutical company noted for its development of drugs targeting rare metabolic disorders, has been under scrutiny for its stock performance between March 26, 2025, and November 4, 2025. During this period, significant concerns arose over the safety and commercial viability of Soleno's lead drug candidate - diazoxide choline extended-release tablets, also known as DCCR. These concerns emerged from results published during the company's Phase 3 clinical trials which reportedly indicated a higher risk of adverse events than previously disclosed by the company.

This information was pivotal, as the company's previous public statements downplayed these safety concerns, which subsequently led to significant financial losses for investors once the truth surfaced. The Schall Law Firm's engagement underscores the gravity of such a situation, offering a potential pathway for recovery for those who participated in the affected trading period.

The Legal Framework

The legal framework of the lawsuit is grounded in violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission. These regulations are designed to protect investors from fraudulent practices by requiring companies to provide truthful information regarding their financial conditions and operations. If allegations in the lawsuit are proven accurate, investors could claim significant damages, reflecting the market's reaction to Soleno's misleading representations.

Call to Action for Affected Investors

Investors who purchased Soleno securities within the defined class period are strongly advised to reach out to the Schall Law Firm to discuss their options. The firm is actively encouraging those affected to join the class action lawsuit, thereby solidifying their rights before the May 5, 2026 deadline, which serves as a significant cut-off for participation. Members of the class will be represented collectively, allowing for a streamlined approach to the complex legal proceedings that lie ahead.

For those looking to connect, Brian Schall of the Schall Law Firm is available for consultations at no charge. Interested individuals can contact the firm through their office in Los Angeles or via their website. By joining this class action, investors can potentially recover losses incurred due to the alleged fraud.

Conclusion

As this case unfolds, it serves as a critical reminder of the importance of vigilance in investment practices and the rights investors hold against misleading corporate statements. The Schall Law Firm’s role in advocating for shareholders reflects a growing trend in protecting investor rights across various industries, offering a beacon of hope for those who've faced unexpected losses. Investors considering participation should act swiftly to secure their positions in this pivotal legal battle.

For more information or to join the case, potential class members are urged to contact the Schall Law Firm directly at 310-301-3335 or via email at [email protected].